Results 191 to 200 of about 349,588 (308)

Impact of Hemoglobin Improvement on Survival in Patients With Myelofibrosis and Anemia Treated With Momelotinib in the SIMPLIFY‐1 and MOMENTUM Trials

European Journal of Haematology, EarlyView.
In this post hoc analysis of the phase 3 SIMPLIFY‐1 and MOMENTUM trials, the number of patients with baseline hemoglobin < 10 g/dL who achieved hemoglobin ≥ 10 g/dL by week 24 with momelotinib, as well as the time to achievement, were evaluated. Patients who were JAK inhibitor naive and/or had moderate anemia were more likely and faster to achieve this
Francesca Palandri, Casey O'Connell, Pankit Vachhani, Donal P. McLornan, Steffen Koschmieder, Juan Carlos Hernandez‐Boluda, Kazuya Shimoda, Shiyuan Zhang, Catherine Ellis, Jessica Lim, Jasmine Sahni, Vikas Gupta   +11 more
wiley   +1 more source

Patient Blood Management in Hematology: Focusing on Platelet Transfusion. [PDF]

J Clin Med
Solves P, Córcoles M, Soriano M, Lamas B, Martínez-Campuzano D, Asensi P, Gómez-Seguí I, de la Rubia J.   +7 more
europepmc   +1 more source

The Effect of Polycythemia Vera on Pregnancy Complications. The Analysis of an American Population Database With Over 9 Million Deliveries

European Journal of Haematology, EarlyView.
ABSTRACT Objectives Polycythemia Vera (PV) is characterized by overproduction of erythrocytes, leading to a hypercoagulable state. Evidence regarding associations between PV and pregnancy outcomes is limited. The aim of our study was to provide robust evidence regarding the prevalence of pregnancy complications in women with PV.
Noah Margolese, Sarah Al‐Rayes, Shaonie Ton‐Leclerc, Ahmad Badeghiesh, Haitham Baghlaf, Michael H. Dahan   +5 more
wiley   +1 more source

Association Between Platelet Transfusion and ICU Mortality Within 28 Days Among Patients With Intracranial Hemorrhage Complicated by Thrombocytopenia: A Propensity Score-Matched Cohort Study. [PDF]

Med Sci Monit
Qiu D, Wang Z, Hu X, Wang L, Jiang S, Zhang S, Dong Y.   +6 more
europepmc   +1 more source

Feasibility and Safety of Venetoclax for Cytoreduction During Induction Therapy in Newly Diagnosed Acute Promyelocytic Leukemia

European Journal of Haematology, EarlyView.
ABSTRACT Objective This study aimed to evaluate the feasibility and safety of venetoclax as a cytoreductive strategy during induction therapy in newly diagnosed acute promyelocytic leukemia (APL), and to provide an exploratory description of its early efficacy.
Yu Wang, Rong Xiao, Xiaobing Huang, Yi Xiao   +3 more
wiley   +1 more source

Platelet transfusion practice in the intensive care unit: the Nine-I international platelet transfusion survey. [PDF]

Ann Intensive Care
Russell L, Azoulay E, Anthon CT, Pène F, Akella P, Mabrouki A, Puxty K, Nielsen LB, Andreasen JB, Kander T, Sjövall F, Hästbacka J, Hvas CL, Van De Louw A, Chawla S, Bauer PR, Castro P, Povoa P, Coelho L, Fernandez S, Topeli A, Barratt-Due A, Barbaglio C, Kochanek M, Martin-Loeches I, Kentish-Barnes N.   +25 more
europepmc   +1 more source

Sirolimus is effective for paediatric Evans syndrome and secondary autoimmune cytopenias: A retrospective cohort study

British Journal of Haematology, EarlyView.
Maggie McNeill, Camilla Cellarius, Nethmi Illamperuma, Rachelle Zipper, Clarisse Carcao, Jillian M. Baker, Sheila Butchart, Michelle Fantauzzi, Caroline Malcolmson, Reena Pabari, Diandra Rollan, Kathleen Qu, Manuel Carcao   +12 more
wiley   +1 more source

Dose‐Adjusted Treatment With 7‐Day Venetoclax Plus Azacitidine or Decitabine in Patients With Acute Myeloid Leukaemia

European Journal of Haematology, EarlyView.
ABSTRACT Acute myeloid leukaemia (AML) in older or unfit patients is commonly treated with hypomethylating agents (HMA) plus venetoclax (VEN), but prolonged VEN exposure often causes substantial haematological toxicity. We retrospectively analysed 61 elderly AML patients treated with HMA + VEN for 7 (7d), 14 (14d) or > 14 days (> 14d) per cycle.
Laurenz Steiner, Lina S. Silva‐Bermudez, Mahmoud Ghazal, Mohammed Abba, Catharina Gerhards, Georgia Metzgeroth, Alice Fabarius, Stefan Klein, Sebastian Kreil, Nanni Schmitt, Patrick Wuchter, Wolf‐Karsten Hofmann, Alexander Streuer   +12 more
wiley   +1 more source

Real‐world evidence on the safety and effectiveness of thrombopoietin receptor agonists in aplastic anaemia: A descriptive study using Japanese hospital administrative data

British Journal of Haematology, EarlyView.
Kayoko Mizuno, Yutaka Shimazu, Toshiki Fukasawa, Satoru Ito, Yukihiro Nishio, Mami Shimizu, Koji Kawakami   +6 more
wiley   +1 more source

Prospective Study of Targeted Busulfan–Fludarabine Conditioning for Hematopoietic Stem Cell Transplantation in Genetic Rare Diseases

European Journal of Haematology, EarlyView.
ABSTRACT Objectives Genetic rare diseases (GRDs), including chronic granulomatous disease, familial hemophagocytic lymphohistiocytosis, and congenital neutropenia, often require hematopoietic stem cell transplantation (HSCT) as the only curative option.
Bo Kyung Kim, Kyung Taek Hong, Jung Yoon Choi, Hyun Jin Park, Kyung‐Sang Yu, In‐Jin Jang, Hyoung Jin Kang   +6 more
wiley   +1 more source